Drug Discovery for Kidney Channelopathies
Creative Bioarray is committed to helping clients develop drugs for the treatment of kidney channelopathies, including Bartter's syndrome (BS) including types II–IV, Dent disease type 1, and EAST/SESAME syndrome. Based on the mature technology platform, our excellent scientific research team targets ion channels to develop effective therapies for kidney channelopathies.
Introduction
Ion channels are critical to kidney function, and their dysregulation contributes to several different kidney diseases. In the kidney, ion channel diversity plays a key role in the reabsorption or excretion of sodium and potassium along the nephron, magnesium homeostasis, control of water reabsorption in the collecting ducts, and determination of glomerular permeability. The transient receptor potential (TRP) superfamily, chloride channels, etc., have been shown to be effective therapeutic targets for some kidney channelopathies.
Specific drugs targeting ion channels are not only important tools for elucidating disease pathology, but may also lead to new, mechanism-based therapies for diseases of all tissues, including the kidneys, brain, and more. With the discovery of new mutation sites in ion channel-related kidney disease genes, the rapid development of genetic diagnostic methods and the development of new drugs, the diagnosis and treatment of ion channel-related kidney disease will be more accurate and efficient.
Fig. 1 The renal channelopathies—by location within the nephron. (Loudon, 2014)
Drug Development for Kidney Channelopathies
CLCNKB (ClC-Kb), BSDN (Barttin), ROMK1 (Kir1.1), CLCN5 (ClC-5), KCNJ11 (Kir4.1) and other genes encoding ion channels have been proved to be involved in the occurrence of several kidney channelopathies, such as Bartter's syndrome (BS) including types II-IV, Dent disease type 1, and EAST/SESAME syndrome. Symptomatic therapy aims at restoring electrolyte balance. Some pharmacotherapies have been developed, such as the use of potassium and magnesium supplements to restore electrolyte balance, and the use of potassium diuretics such as spironolactone/eplerenone and amiloride to restore serum K+ concentrations. Our drug development services include, but are not limited to:
- Establishment of transient expression system of the specific ion channel in cultured mammalian cells.
- Functional characterization of ion channel mutations leading to kidney channelopathies.
- Analysis of genotype-phenotype relationships in kidney channelopathies.
- Development of selective channel openers through pharmacogenetic approaches.
- Development of pharmacological chaperones.
Advantages
- Doctor-level R&D team—professional and efficient technical consultation
- Efficient scientific services—one-stop comprehensive solutions
- Professional process optimization—effectively shorten the development cycle
- Project leader system—regular meetings and communication
With advantages in the field of ion channel analysis, Creative Bioarray provides the world's leading drug research and development services for the development of innovative drugs in the preclinical stage of kidney channelopathies for global biotechnology and pharmaceutical clients. If you need our scientific services and technical support, please contact us for more details.
Reference
- Loudon, K. W.; Fry, A. C. The renal channelopathies. Annals of Clinical Biochemistry, 2014, 51(4): 441-458.
